171 related articles for article (PubMed ID: 25323905)
1. DNA hypomethylation-mediated overexpression of carbonic anhydrase 9 induces an aggressive phenotype in ovarian cancer cells.
Sung HY; Ju W; Ahn JH
Yonsei Med J; 2014 Nov; 55(6):1656-63. PubMed ID: 25323905
[TBL] [Abstract][Full Text] [Related]
2. Aberrant hypomethylation-mediated AGR2 overexpression induces an aggressive phenotype in ovarian cancer cells.
Sung HY; Choi EN; Lyu D; Park AK; Ju W; Ahn JH
Oncol Rep; 2014 Aug; 32(2):815-20. PubMed ID: 24920423
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of mucin 13 due to promoter methylation promotes aggressive behavior in ovarian cancer cells.
Sung HY; Park AK; Ju W; Ahn JH
Yonsei Med J; 2014 Sep; 55(5):1206-13. PubMed ID: 25048476
[TBL] [Abstract][Full Text] [Related]
4. Synaptotagmin-like protein 2 gene promotes the metastatic potential in ovarian cancer.
Sung HY; Han J; Ju W; Ahn JH
Oncol Rep; 2016 Jul; 36(1):535-41. PubMed ID: 27220283
[TBL] [Abstract][Full Text] [Related]
5. Aberrant DNA methylation in the IFITM1 promoter enhances the metastatic phenotype in an intraperitoneal xenograft model of human ovarian cancer.
Kim NH; Sung HY; Choi EN; Lyu D; Choi HJ; Ju W; Ahn JH
Oncol Rep; 2014 May; 31(5):2139-46. PubMed ID: 24676393
[TBL] [Abstract][Full Text] [Related]
6. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
[TBL] [Abstract][Full Text] [Related]
7. Aberrant epigenetic regulation of GABRP associates with aggressive phenotype of ovarian cancer.
Sung HY; Yang SD; Ju W; Ahn JH
Exp Mol Med; 2017 May; 49(5):e335. PubMed ID: 28524180
[TBL] [Abstract][Full Text] [Related]
8. Aberrant Hypomethylation of Solute Carrier Family 6 Member 12 Promoter Induces Metastasis of Ovarian Cancer.
Sung HY; Yang SD; Park AK; Ju W; Ahn JH
Yonsei Med J; 2017 Jan; 58(1):27-34. PubMed ID: 27873492
[TBL] [Abstract][Full Text] [Related]
9. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma.
Gupta A; Godwin AK; Vanderveer L; Lu A; Liu J
Cancer Res; 2003 Feb; 63(3):664-73. PubMed ID: 12566312
[TBL] [Abstract][Full Text] [Related]
10. Promoter hypermethylation influences the suppressive role of maternally expressed 3, a long non-coding RNA, in the development of epithelial ovarian cancer.
Sheng X; Li J; Yang L; Chen Z; Zhao Q; Tan L; Zhou Y; Li J
Oncol Rep; 2014 Jul; 32(1):277-85. PubMed ID: 24859196
[TBL] [Abstract][Full Text] [Related]
11. Methylation of the CA9 promoter can modulate expression of the tumor-associated carbonic anhydrase IX in dense carcinoma cell lines.
Jakubicková L; Biesová Z; Pastoreková S; Kettmann R; Pastorek J
Int J Oncol; 2005 Apr; 26(4):1121-7. PubMed ID: 15754010
[TBL] [Abstract][Full Text] [Related]
12. Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with platinum resistance in ovarian cancer.
de Leon M; Cardenas H; Vieth E; Emerson R; Segar M; Liu Y; Nephew K; Matei D
Gynecol Oncol; 2016 Sep; 142(3):539-47. PubMed ID: 27374141
[TBL] [Abstract][Full Text] [Related]
13. Aberrant methylation of RASSF2A in tumors and plasma of patients with epithelial ovarian cancer.
Wu Y; Zhang X; Lin L; Ma XP; Ma YC; Liu PS
Asian Pac J Cancer Prev; 2014; 15(3):1171-6. PubMed ID: 24606436
[TBL] [Abstract][Full Text] [Related]
14. Demethylation by 5-aza-2'-deoxycytidine in colorectal cancer cells targets genomic DNA whilst promoter CpG island methylation persists.
Mossman D; Kim KT; Scott RJ
BMC Cancer; 2010 Jul; 10():366. PubMed ID: 20618997
[TBL] [Abstract][Full Text] [Related]
15. [E-cadherin promoter methylation and demethylation in epithelial ovarian carcinoma cells].
Qu PP; Shi Z; Li N
Zhonghua Fu Chan Ke Za Zhi; 2009 Jul; 44(7):538-41. PubMed ID: 19957556
[TBL] [Abstract][Full Text] [Related]
16. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic silencing of DKK2 and Wnt signal pathway components in human ovarian carcinoma.
Zhu J; Zhang S; Gu L; Di W
Carcinogenesis; 2012 Dec; 33(12):2334-43. PubMed ID: 22964660
[TBL] [Abstract][Full Text] [Related]
18. Aberrant promoter methylation and expression of UTF1 during cervical carcinogenesis.
Guenin S; Mouallif M; Deplus R; Lampe X; Krusy N; Calonne E; Delbecque K; Kridelka F; Fuks F; Ennaji MM; Delvenne P
PLoS One; 2012; 7(8):e42704. PubMed ID: 22880087
[TBL] [Abstract][Full Text] [Related]
19. Novel miRNA genes deregulated by aberrant methylation in ovarian carcinoma are involved in metastasis.
Loginov VI; Pronina IV; Burdennyy AM; Filippova EA; Kazubskaya TP; Kushlinsky DN; Utkin DO; Khodyrev DS; Kushlinskii NE; Dmitriev AA; Braga EA
Gene; 2018 Jul; 662():28-36. PubMed ID: 29631007
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts.
Srivastava P; Paluch BE; Matsuzaki J; James SR; Collamat-Lai G; Taverna P; Karpf AR; Griffiths EA
Epigenetics; 2015; 10(3):237-46. PubMed ID: 25793777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
